Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment

PHASE3TerminatedINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

November 30, 2011

Conditions
Type 2 Diabetes MellitusRenal Impairment
Interventions
DRUG

dutogliptin

100 mg QD

DRUG

dutogliptin

200 mg QD

DRUG

placebo

DRUG

sitagliptin

25 mg QD

DRUG

sitagliptin

50 mg QD

Trial Locations (43)

Unknown

Phenomix Investigational Site 115, Tempe

Phenomix Investigational Site 121, Long Beach

Phenomix Investigational Site 110, Lynwood

Phenomix Investigational Site 118, Lynwood

Phenomix Investigational Site 119, Orange

Phenomix Investigational Site 109, Palm Springs

Phenomix Investigational Site 122, Whittier

Phenomix Investigational Site 112, Lauderdale Lakes

Phenomix Investigational Site 104, Ocala

Phenomix Investigational Site 116, Pembroke Pines

Phenomix Investigational Site 101, Augusta

Phenomix Investigational Site 117, Honolulu

Phenomix Investigational Site 102, Baton Rouge

Phenomix Investigational Site 100, Rockville

Phenomix Investigational Site 125, Rockville

Phenomix Investigational Site 114, Springfield Gardens

Phenomix Investigational Site 120, Winston-Salem

Phenomix Investigational Site 107, Columbia

Phenomix Investigational Site 111, Nashville

Phenomix Investigational Site 103, Fort Worth

Phenomix Investigational Site 106, Houston

Phenomix Investigational Site 108, San Antonio

Phenomix Investigational Site 113, Alexandria

Phenomix Investigational Site 208, Kemerovo

Phenomix Investigational Site 203, Moscow

Phenomix Investigational Site 204, Moscow

Phenomix Investigational Site 209, Moscow

Phenomix Investigational Site 211, Moscow

Phenomix Investigational Site 205, Novosibirsk

Phenomix Investigational Site 207, Perm

Phenomix Investigational Site 206, Petrozavodsk

Phenomix Investigational Site 200, Saint Petersburg

Phenomix Investigational Site 201, Saint Petersburg

Phenomix Investigational Site 210, Saint Petersburg

Phenomix Investigational Site 212, Saint Petersburg

Phenomix Investigational Site 213, Saint Petersburg

Phenomix Investigational Site 304, Chernivtsi

Phenomix Investigational Site 300, Kyiv

Phenomix Investigational Site 301, Kyiv

Phenomix Investigational Site 306, Kyiv

Phenomix Investigational Site 302, Odesa

Phenomix Investigational Site 303, Vinnytsa

Phenomix Investigational Site 307, Zaporizhzhya

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Forest Laboratories

INDUSTRY

lead

Phenomix

INDUSTRY